MARY1
MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM (human 5-HT2BR) . MARY1 induces renal mitochondrial biogenesis (MB) and enhances renal mitochondrial function by increasing mitochondrial respiratory capacity, mitochondrial protein levels, and mitochondrial number in renal proximal tubular cells (RPTCs) . MARY1 induces MB through 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK cell signaling pathways in RPTCs. MARY1 can be used to study renal diseases associated with metabolic and mitochondrial dysfunction[1].
Product Specifications
UNSPSC
12352005
Target
5-HT Receptor; Akt; ERK; MEK; PGC-1α; PI3K; Ras
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Neuronal Signaling; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Smiles
FC1=C(C(F)=CC(F)=C1)C(NC2=NC(C(N3CCN(CC3)C)=O)=CC=C2)=O
Molecular Formula
C18H17F3N4O2
Molecular Weight
378.35
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
5-HT2 Receptor
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
